In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease
Dose reduction or discontinuation may be necessary if you develop: Persistent, intolerable gastrointestinal symptoms despite supportive measures Acute pancreatitis (discontinue permanently) Severe hypoglycemia, particularly if taking concurrent insulin or sulfonylureas Acute kidney injury or worsening renal function Gallbladder disease symptoms (abdominal pain, jaundice) Diabetic retinopathy complications (particularly with semaglutide) Severe hypersensitivity reactions including anaphylaxis or angioedema Pregnancy or plans for pregnancy (for semaglutide, discontinue at least two months before planned conception
These medications have been costing employers between $617 and $766 per fill through traditional insurance channels
Ozempic is part of a class of drugs called GLP-1s, which I wont get too deep into, as many people are burned out from even hearing about GLP-1s from 2023 (me included)
The Upgrade Question, Answered Honestly Retatrutide is almost certainly going to be the more powerful drug when head-to-head data eventually arrives
